Drug-Drug Interactions and Clinical Outcomes Captured by Climate-HIV
Research type
Research Study
Full title
Using Climate-HIV to understand real-world drug-drug interactions and clinical outcomes for people living with HIV
IRAS ID
225435
Contact name
Melissa Myland
Contact email
Sponsor organisation
ViiV Healthcare
Duration of Study in the UK
0 years, 11 months, 2 days
Research summary
People living with HIV (PLWHIV) are living longer and being diagnosed with additional illnesses which require treatment. New therapy in HIV aims to reduce the potential for interactions between treatment for HIV and those additional diseases. A study using data collected by clinicians to support patient care indicates that up to 40% of PLWHIV may have at least one potential interaction due to prescription of HIV and non-HIV treatment at the same time. Little research has been conducted into the occurrence of these interactions in routine clinical care. This study will use data from medical records used for the management of HIV in the UK to understand potential interactions between HIV treatments and treatments for additional illnesses, as well as the occurrence of additional diseases.
Additionally, effectiveness of newer treatments (such as dolutegravir [DTG]) has only been described in one study derived from routine clinical care. Changes in viral load between baseline and follow-up (24, 48, 96 weeks; last measurement) will be determined for patients either using DTG as a first treatment or switching to DTG from a previous HIV treatment.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
17/WM/0271
Date of REC Opinion
13 Jul 2017
REC opinion
Favourable Opinion